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	 Several	 simple,	 sensitive,	 accurate	 and	 inexpensive	 spectrophotometric	 and
spectrofluorimetric	methods	were	developed	 for	 the	determination	of	propafenone	HCl	and
diltiazem	HCl	using	4‐chloro‐7‐nitrobenzofurazan	(NBD‐Cl)	accompanied	with	kinetic	study,
either	in	pure	form	or	in	pharmaceutical	preparations.	In	this	work,	the	cited	drugs	react	with
(NBD‐Cl)	 in	 presence	 of	 borate	 buffer	 of	 pH	 =	 7.6	 at	 a	 fixed	 time	 of	 30	 minutes	 on
thermostated	 water	 bath	 at	 (75‐80	 °C).	 The	 absorbance	 was	 measured	 using
spectrophotometric	 technique	 at	 489	 and	 481	 nm	 for	 propafenone	 HCl	 and	 diltiazem	 HCl,
respectively,	 or	 by	 using	 spectrofluorimetric	 technique	 after	 dilution	 at	 the	 specific
wavelength	of	excitation	and	emission.The	calibration	curves	were	linear	in	the	range	of	4‐44,
16‐96	 µg/mL	 when	 using	 spectrophotometric	 method,	 and	 0.4‐3.6,	 1.6‐8.8	 µg/mL	 when
spectrofluorimetric	method	was	applied	for	propafenone	HCl	and	diltiazem	HCl,	respectively.
The	 limit	of	quantitation	and	 the	 limit	of	detection	were	also	 calculated.	The	methods	were
applied	 successfully	 to	 commercial	 dosage	 form	 and	 can	 be	 further	 applied	 for	 their
determination	on	a	large	scale	in	quality	control	laboratories.	The	obtained	results	statistically
agreed	with	those	obtained	by	reference	methods.	The	determination	of	the	studied	drugs	by
the	 fixed	concentration	and	rate	constant	methods	 is	 feasible	with	the	calibration	equations
obtained,	but	the	fixed	time	method	proves	to	be	more	applicable.	
Diltiazem	HCl	
Propafenone	HCl	
Spectroflourimetric	
Spectrophotometric	
Kinetic	determination	
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1.	Introduction	
	
Propafenone	 hydrochloride,	 chemically	 known	 as	 1‐[2‐
[(2RS)‐2‐hydroxy‐3‐(propylamino)propoxy]phenyl]‐3‐phenyl‐
propan‐1‐onehydrochloride	(Scheme	1)	[1].	It	is	a	class	IC	(Na+	
channel	 block)	 antiarrhythmic	 with	 some	 negative	 inotropic	
and	 beta‐adrenoceptor	 blocking	 activity.	 It	 is	 used	 in	 the	
management	 of	 supraventricular	 and	 ventricular	 arrhythmias	
[2].	Propafenone	HCl	is	official	and	can	be	determined	in	British	
Pharmacopoeia	 (BP)	 [1]	 and	 in	 United	 States	 Pharmacopoeia	
(USP)	 [3]	 by	 non‐aqueous	 titration	 using	 perchloric	 acid	
determining	end‐point	potentiometrically.		
A	 spectrofluorimetric	 method	 was	 described	 for	 the	
determination	 of	 propafenone	 hydrochloride	 using	N’‐methyl	
nicotinamide	 chloride	 (NMNCl)	 in	 the	 presence	 of	 alkali,	
followed	 by	 addition	 of	 formic	 acid,	where	 highly	 fluorescent	
reaction	products	were	produced	and	measured	quantitatively	
at	 λem	 409	 nm	 (λex	 =	 310	 nm)	 [4].	 HPLC	 techniques	 were	
extensively	 used	 for	 determination	 of	 propafenone,	
propafenone	 enantiomers	 and	 propafenone	 metabolites	
inbiological	 fluids	 using	 UV	 [5],	 fluorimetric	 [6]	 or	
electrochemical	 detections	 [7].	 LC‐flourescence	 detection	 [8]	
and	 LC‐UV	 [9]	 detection	 were	 adopted	 for	 determination	 of	
propafenone.	 LC‐MS	 [10],	 HPLC‐MS	 [11],	 GC‐MS	 [12],	 GC‐
electron‐capture	 detection	 [13],	 TLC	 [14]	 and	 capillary	
electrophoresis	 [15]	 were	 also	 used	 for	 determination	 of	 the	
drug	 and	 its	 metabolites	 in	 pharmaceutical	 formulations	 and	
biological	 fluids.	Propafenone	was	determined	 in	blood	serum	
using	adsorptive‐stripping	voltammetry	[16].		
	
	
C21H27NO3.HCl	
Propafenone	hydrochloride,	1‐[2‐(2‐Hydroxy‐3‐
(propylamino)propoxy)phenyl]‐3‐phenyl‐1‐propanone	hydrochloride	
	
	
	
C22H26N2O4	S.	HCl	
Diltiazemhydrochloride,	(2S,3S)‐(+)‐cis‐3‐Acetoxy‐5‐(2‐
dimethylaminoethyl)‐2,3‐dihydro‐2‐(4‐methoxyphenyl)‐1,5‐benzothiazepin‐
4(5H)‐one	hydrochloride	
	
Scheme	1	
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A	 simple	 differential	 oscillographic	 voltammetric	 method	
was	 reported	 for	 the	 determination	 of	 propafenone	
hydrochloride	 in	 tablets	 [17].	 Diltiazemhydrochlorideis	
(2S,3S)‐5‐[2‐(dimethylamino)	 ethyl]‐2‐(4‐methoxyphenyl)‐4‐
oxo‐2,3,4,5‐tetrahydro‐1,5‐benzothiazepin‐3‐yl	 acetatehydro‐
chloride	 [1].	 Diltiazem	 is	 a	 benzothiazepine	 calcium‐channel	
blocker.	It	is	a	peripheral	and	coronary	vasodilator	with	limited	
negative	 inotropic	 activity.	 Diltiazeminhibits	 cardiac	
conduction,	 particularly	 at	 the	 sino‐atrial	 and	 atrioventricular	
nodes.	 It	 is	 used	 in	 the	 management	 of	 angina	 pectoris	 and	
hypertension	 [2]. The	 BP	 specifies	 non‐aqueous	 titration	
technique	 detecting	 the	 end	 point	 potentio‐metrically	 for	 its	
determination	 [1],	 while	 USP	 describes	 liquid	 chromatographic	
method	[3].		
Ion‐pair	 complex	 formation	 reactions	 were	 used	 for	
assaying	 diltiazem	 in	 its	 dosage	 forms	 using	 methyl	 orange,	
eriochrome	black	I,	mordant	black	II,	tropeolin,	picric	acid	[18]	
,orange	II,	alizarin	red	S	[19],	bromothymol	blue,	bromophenol	
blue,	 bromocresolgreen	 [20],	 chromotrope	2R	 and	 rosebengal	
[21].	Also	diltiazem	was	determined	by	its	reaction	with	cobalt	
thiocyanate	 at	 pH	 =	 3‐5	 forming	 ternary	 complex	 which	 was	
extracted	 and	 measured	 at	 627	 nm	 [22].	 Diltiazem	 hydro‐
chloride	was	determined	simultaneously	using	 first‐order	and	
second‐order	 derivative	 UV‐	 spectrophotometric	 methods	
[23].Also	 it	 was	 determined	 in	 commercial	 dosage	 forms	
through	 the	 reaction	 of	 the	 tertiary	 amino	 group	 of	 the	 drug	
with	 sodium	hypochlorite	 to	 form	 the	 chloro	 drug	 derivative,	
which	 reacts	 with	 starch	 and	 potassium	 iodide	 in	 sodium	
bicarbonate	 forming	 blue	 color	 measured	 at	 540	 nm	 [24].	
Spectrophotometric	 determination	 of	 diltiazem	 with	 kinetic	
study	was	reported	[25].	The	method	was	based	on	two‐stage	
reaction	of	the	drug	with	hydroxylamine	and	ferric	salt	with	the	
formation	 of	 red	 colored	 complex.	 Oxidation‐reduction	
reactions	 were	 widely	 used	 for	 diltiazem	 assay	 in	 pure	 and	
pharmaceutical	 dosage	 forms.	 Diltiazem	 was	 oxidized	 using	
sodium	metavanadate	measuring	 absorbance	 at	 750	nm	 [26].	
Also	it	was	assayed	through	oxidation	of	the	drug	with	iron(III)	
in	acidic	medium	where	the	liberated	iron(II)	reacts	with	1,10‐
phenanthroline	 or	 2,2‐bipyridyl	 to	 form	 stable	 complexes	
measured	 at	510	and	520	nm,	 respectively	 [27].	El‐Didamony	
described	 three	 spectrophotometric	 methods	 based	 on	
oxidation	 of	 diltiazem	 with	 N‐bromosuccinimide	 (NBS)	 and	
determination	of	unconsumed	NBS	by	measuring	the	decrease	
in	absorbance	of	amaranth	dye	or	by	cerric	ammonium	sulfate	
and	subsequent	determination	of	the	unconsumed	oxidant	by	a	
decrease	in	the	color	of	chromotrope	2R	or	rhodamine	6G	[28].	
Also	diltiazem	was	oxidized	by	copper(II)	 in	buffered	solution	
(pH	 =	 7.0)	 where	 the	 copper(I)	 produced	 reacts	 with	 4,4′‐
dicarboxy‐2,2′‐biquinoline	acid	and	 the	 complexes	 formed	are	
spectrophotometrically	 measured	 at	 558	 nm	 [29].	 HPLC	 was	
extensively	 described	 for	 determination	 of	 diltiazem	 HCl	 in	
pharmaceutical	 preparations	 [30],	 biological	 fluids	 [31]	 using	
UV	 or	 flourimetric	 [32]	 detections.	 HPLC	 was	 also	 used	 for	
determination	of	diltiazem	with	its	metabolites	either	in	serum	
[33]	or	plasma	[34].HPLC	was	used	for	enantiomeric	separation	
of	 diltiazem	 enantiomers	 in	 pharmaceuticals	 [35].	 RP‐HPLC	
[36],	LC	[37],	HPTLC	[38],	GC	[39]	and	capillary	electrophoresis	
[40]	 were	 also	 applied	 for	 determination	 of	 diltiazem	 in	
biological	 fluids,	 tissues	 and	 pharmaceutical	 formulations.	
Tetraphenylborate	was	used	to	form	ion‐pair	complex	with	the	
drug	 as	 an	 electroactive	material	 to	 prepare	 four	 types	 of	 ion	
selective	 electrodes	 [41].	 Ion‐selective	 electrodes	 were	 also	
applied	 for	 determination	 of	 diltiazem	 HCl	 using	 PVC	
membrane	 electrodes	 based	 on	 ion	 pair	 complexes	 formation	
with	 sodium	 Dinonylnaphthalene	 sulphonic	 acid	 [42]	 or	
tetraphenylborate	 [43].	 Diltiazem	 was	 also	 determined	 using	
Nafion‐modified	glassy	carbon	electrode	[44].	Diltiazem	can	be	
measured	by	adsorptive	stripping	voltammetry	[45].	
	
	
In	 this	 research,	 spectrophotometric,	 spectrofluorimetric	
methods	were	developed	for	the	determination	of	propafenone	
HCl	and	diltiazem	HCl	using	NBD‐Cl	accompanied	with	kinetic	
study.	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
A	 Shimadzu	 recording	 spectrophotometer	 UV	 1800	
equipped	with	10	mm	matched	quartz	cells	was	employed	for	
all	absorbance	measurements.	Perkin‐Elmer	LS45	fluorescence	
spectrophotometer	equipped	with	a	pulsed	xenon	lamp	and	10	
mm	matched	quartz	cells.		
	
2.2.	Materials	and	reagents	
	
Chemicals	 of	 analytical	 grade	 and	 double	 distilled	 water	
were	 used	 throughout	 the	 work.	 Propafenone	 HCl	 and	
Diltiazem	HCl	obtained	from	Kahira	Pharm.	and	Chem.	Ind.	Co.,	
under	 the	 license	 from	 Abott	 Laboratories,	 Egypt	 and	 EPICO,	
Egypt,	respectively.	
4‐Chloro‐7‐nitrobenzen‐2‐oxa‐1,3‐diazole	 (NBD‐Cl)	
(Aldrich),	 a	 fresh	 solution	 (0.1%	 w/v)	 in	 methanol,	 was	
prepared	by	dissolving	0.1g	in	100	mL	methanol.		
Borate	buffer	pH	=	7.6	was	prepared	by	dissolving	2.5	g	of	
sodium	 chloride,	 2.85	 g	 of	 sodium	 tetraborate	 and	 10.5	 g	 of	
boric	acid	in	sufficient	water	to	produce	1000	mL	[1].	
	
2.3.	Standard	solutions	
	
0.4	mg/mL	solutions	of	propafenone	HCl	and	diltiazem	HCl	
were	 prepared	 by	 dissolving	 10	 mg	 of	 the	 drugs	 in	 25	 mL	
distilled	water.	
	
2.4.	Pharmaceutical	preparations	
	
‐Rytmonorm®	 tablets	 (Kahira	 pharm,	 and	 Chem.	 Ind.	 Co.,	
under	 the	 license	 from	 Abott	 Laboratories,	 Egypt)	 labeled	 to	
contain	150mg	Propafenone	HCl	per	tablet.	
‐Altiazem®	tablets	(EIPICo,	Egypt)	labeled	to	contain	60	mg	
diltiazem	HCl	per	tablet.	
‐Delay‐tiazem®	capsules	(Galaxo	Smith	Kline,	Egypt)	labeled	
to	contain	120	mg	diltiazem	HCl	per	capsule.	
	
2.5.	General	procedure	
	
2.5.1.	Spectrophotometric	procedure	
	
Accurately	 measured	 aliquots	 of	 standard	 solutions	 were	
transferred	 into	a	 series	of	10	mL	volumetric	 flasks,	 and	 then	
specified	 amounts	 of	 borate	 buffer	 pH	 =	 7.6	 and	 NBD‐Cl	
solution	(0.1%	w/v)	were	added.	The	mixtures	were	heated	for	
30	 minutes	 in	 water	 bath	 (75‐80	 oC).	 Cool	 the	 solutions	 and	
acidify	with	1	M	HCl.	The	reaction	products	were	diluted	to	10	
mL	with	methanol	 and	 the	 absorbance	was	measured	 at	 489	
and481	 nm	 for	 propafenone	 HCl	 and	 diltiazem	 HCl,	
respectively,	 against	 a	 reagent	 blank	 prepared	 in	 the	 same	
manner,	Table	1.	
	
2.5.2.	Spectroflourimetric	procedure	
	
Aliquots	 of	 standard	 solutions	 were	 treated	 as	 in	
spectrophotometric	 procedure	 and	 1	 mL	 of	 the	 previously	
derivatized	 solutions	were	 transferred	 into	 another	 set	 of	 10	
mL	volumetric	flasks	and	diluted	up	to	the	mark	with	methanol.	
The	 fluorescence	 intensity	 was	 measured	 at	 the	 specific	
wavelength	of	excitation	and	emission	against	a	reagent	blank	
treated	similarly,	Table	1.	
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Table	1.	Analytical	parameters	for	determination	of	propafenone	HCl	and	diltiazem	HCl	using	NBD‐Cl.	
Parameter	 Propafenone	HCl	 Diltiazem	HCl	
Linearity	range	for	spectrophotometric	method	(g/mL)	 4‐44	 16‐96	
Linearity	range	for	spectroflourimetric	method	(g/mL)	 0.4‐3.6	 1.6‐8.8	
Buffer	pH	=	7.6	volume	(mL)	 2 3	
Volume	of	0.1%	w/v	NBD‐Cl	(mL)	 1 2	
Temperature	(oC)	 75‐80 75‐80	
Time	of	heating	(min.)	 30 30	
Volume	of	1M	HCl	(mL)	 0.5 1	
λ	max(nm)	 489	 481	
λ	ex	(nm)	 481	 476	
λem(nm)	 540	 536	
	
	
2.5.3.	For	pharmaceutical	formulations	
	
For	 tablets:	 Ten	 tablets	 were	 powdered	 and	 an	 amount	
equivalent	 to	10	mg	propafenone	HCl	 and	diltiazem	HCl	were	
shaken	with	10	mL	distilled	water,	then	filtered	and	diluted	to	
25	mL	with	distilled	water.	
For	capsules:	An	accurately	weighted	amount	of	 the	mixed	
contents	 of	10	 capsules	 equivalent	 to	10	mg	of	diltiazem	HCl,	
were	 shaken	 with	 10	 mL	 distilled	 water,	 then	 filtered	 and	
diluted	to	25	mL	with	distilled	water	
The	 assay	 was	 completed	 as	 under	 general	 procedure	 by	
applying	standard	addition	technique.	
	
3.	Results	and	discussion	
	
4‐Chloro‐7‐nitrobenzofurazan	 which	 is	 also	 known	 as	 4‐
chloro‐7‐nitrobenzo‐2‐oxa‐1,	 3‐diazole	 (NBD‐Cl),	 is	 an	
electroactive	halide	 reagent;	 it	has	been	used	as	a	 fluorogenic	
or	chromogenic	reagent	in	pharmaceutical	analysis.	 
The	 analysis	 of	 different	 compounds	 or	 drugs	 either	 in	
pharmaceuticals	or	 in	biological	 samples	was	performed	after	
derivatization	with	NBD‐Cl	followed	by	measuring	the	resulted	
product	 by	 means	 of	 spectrophotometry	 [46‐49],	
Spectrofluorimetry	[50‐52],	HPLC	as	in	determination	aliphatic	
amines	[53].	
It	has	also	been	used	in	charge	transfer	reactions	due	to	its	
electrophilic	 properties,	 where	 it	 acts	 as	 ‐acceptor	 for	
determination	 of	 some	 β‐blockers	 [54],	 some	 skeletal	 muscle	
relaxant	and	antihistaminic	drugs	[55].	 
NBD‐Cl	 was	 also	 applied	 for	 the	 kinetic	 determination	 of	
clindamycin	 phosphate	 [56],	 tramadol	 hydrochloride	 [57],	
dothiepin	 hydrochloride	 [58],	 trimetazidinedihydrochloride	
[59],	 befunolol	 hydrochloride	 [60],	 isoxsuprine	 [61],	
ciprofloxacin	 hydrochloride,	 norfloxacin	 [62],	 acetylcysteine,	
carbocisteine	[63],	fluvastatin	[64],	betahistinedihydrochloride	
and	etilefrine	hydrochloride	[65].		
In	this	work,	spectrophotometric,	spectrofluorimetric	methods	
were	developed	for	the	determination	of	propafenone	HCl	and	
diltiazem	HCl	using	NBD‐Cl	accompanied	with	kinetic	study.	
The	 presence	 of	 nitro	 group	 in	 6	 or	 7	 position	 in	 NBD‐Cl	
molecule	 induces	 a	 direct	 and/or	 indirect	 electrophilic	
reactivity.	 This	 can	 be	 also	 attributed	 to	 the	 strongly	
unsaturated	 character	 of	 nitro‐benzofurazone	 system	 [66].	
Propafenone	HCl	and	diltiazemHCl	 reacted	directly	with	NBD‐
Cl	as	they	already	contain	amino	groups.	The	reaction	product	
has	 yellowish	 brown	 color	 with	 λmax	 at	 489	 and481	 nm,	 for	
propafenone	HCl	and	diltiazem	HCl,	respectively.	Moreover	the	
reaction	product	 exhibited	 strong	 fluorescence	 at	 λem	 540	nm	
(λex	=	481	nm)	and	λem	536	nm	(λex	=	476	nm)	for	propafenone	
HCl	 and	 diltiazem	 HCl,	 respectively,	 Figure	 1	 and	 2.	 The	
suggested	mechanism	of	reaction	can	be	interpreted	in	Scheme	
2.	
	
3.1.	Method	development	
	
Investigations	 were	 carried	 out	 to	 establish	 the	 most	
favorable	conditions.	
	
	
Figure	1.	Absorption	spectra	of	the	reaction	between	NBD‐Cl	(0.1%	w/v)	
and	40	g/mL	propafenone	HCl,	56	g/mL	diltiazem	HCl.	
	
	
	
	
Figure	 2.	 Excitation	 and	 emission	 spectra	 of	 the	 reaction	 between	 (0.1%	
w/v)	NBD‐Cl	and	2.4	μg/mL	propafenone	HCl,	4.8	μg/mL	diltiazem	HCl.	
	
	
3.1.1.	Effect	of	pH	
	
Different	borate	buffers	 in	a	pH	range	of	7‐9	and	different	
bases	 such	 as	 disodium	 hydrogen	 phosphate,	 sodium	
bicarbonate,	 sodium	 acetate,	 and	 borax	 were	 tried.	 The	 best	
results	were	obtained	on	using	2	and	3	mL	borate	buffer	of	pH	
=	7.6.	
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Scheme	2	
	
	
Table	2.	Spectral	data	for	determination	of	propafenone	HCl	and	diltiazem	HCl	using	NBD‐Cl.	
Items	
Spectrophotometric	method	 Spectrofluorimetric	method	
Propafenone	HCl Diltiazem	HCl Propafenone	HCl	 Diltiazem	HCl
Linearity	range	(µg/mL)	 4‐44	 16‐96 0.4‐3.6 1.6‐8.8
Apparent	molar	absorptivity*	(mol‐1cm‐1)	 7.894	×	103	 3.524	×	103	 	 	
Sandell's	sensitivity	(mg/mL	per	0001A)	 2.336	×	10‐3 7.814	×	10‐4 	
Limit	of	detection	(µg/mL)	 1.21 4.71 0.115 0.407
Limit	of	quantification	(µg/mL)	 3.66 14.29 0.349 1.23	
Regression	equation**	 	
Slope	(b)	 0.0197 0.0070 84.353 23.846
Intercept	(a)	 0.0827 0.0428 15.897 33.500
Correlation	coefficient	(r)	 0.9999	 0.9999	 0.9999	 0.9997	
*	Calculated	on	the	basis	of	the	molecular	weight	of	the	drug.	
**	A	=	a	+	bC	
	
	
3.1.2.	Effect	of	NBD‐Cl	concentration	
	
1	and	2	mL	0.1%	w/v	NBD‐Cl	was	sufficient	for	production	
of	maximum	and	reproducible	color	 intensity	for	propafenone	
HCl	and	diltiazem	HCl,	respectively.		
	
3.1.3.	Effect	of	HCl	molarity	and	volume	
	
The	reaction	products	must	be	acidified	to	pH	=	2	using	HCl	
before	measurement,	in	order	to	change	NBD‐OH	to	NBD‐OCH3	
[66,46].	It	was	found	that	maximum	absorbance	readings	were	
obtained	on	using	0.5	and	1.0	mL	1	M	HCl	for	propafenone	HCl	
and	diltiazem	HCl,	respectively.	
	
3.1.4.	Effect	of	temperature	and	time	
	
Following	 the	 color	 development	 from	 ambient	
temperature	(25	5	oC)	to	100	oC,	It	was	found	that	the	reaction	
rate	 was	 very	 slow	 at	 room	 temperature	 and	 complete	 color	
development	 was	 attained	 after	 30	 minutes	 in	 water	 bath	 at	
(75‐80	oC)	for	both	drugs.	Above	80	oC	is	not	preferable	due	to	
precipitation	 of	 the	 product	 on	walls	 of	 tubes	 [67].	 The	 color	
remains	stable	for	up	to	2‐3	hours	for	both	drugs.	
	
3.1.5.	Effect	of	diluting	solvents	
	
Several	organic	solvents	such	as	methanol,	ethanol,	distilled	
water,	 acetone	 and	 acetonitrile	 were	 investigated.	 Methanol	
was	found	to	be	the	most	appropriate	solvent	for	both	drugs	to	
give	the	highest	absorbance	and	more	stability.	
	
3.2.	Method	validation	
	
3.2.1.	Quantification,	accuracy	and	precision	
	
Beer’s	 law	was	obeyed	over	a	concentration	range	of	4‐44	
and	 16‐96	 μg/mL	 for	 propafenone	 HCl	 and	 diltiazem	 HCl,	
respectively.	Besides,	 the	fluorescence	 intensity	showed	 linear	
relationship	from	0.4‐3.6	and	1.6‐8.8	μg/mL	for	the	two	drugs,	
respectively.		
Molar	 absorptivity,	 correlation	 coefficient,	 intercept	 and	
slope	 for	 the	 calibration	 curve,	 detection	 and	 quantification	
limit	were	calculated,	Table	2.	Also	relative	standard	deviation,	
analytical	 standard	 error	 and	 variance	 were	 calculated	 and	
listed	 in	 Table	 3.	 The	 proposed	 methods	 were	 applied	 for	
determination	 of	 the	 selected	 drugs	 in	 their	 pharmaceutical	
preparations	 using	 the	 standard	 addition	 technique,	 Tables	 4	
and	5.	 Results	 obtained	were	 compared	with	 official	methods	
[1,3]	 of	 both	 drugs	 and	 no	 significant	 difference	 was	 found	
between	the	proposed	and	reference	methods,	Table	6.	
	
3.2.2.	Accuracy	and	precision		
	
Accuracy	 and	 precision	 were	 carried	 out	 by	 six	
determinations	at	four	different	concentrations	of	both	drugs	in	
the	same	day	(intra‐day),	and	 in	six	different	days	(inter‐day).	
Percentage	 relative	 standard	deviation	 (R.S.D.	%)	as	precision	
and	 percentage	 relative	 error	 (Er	 %)	 as	 accuracy	 of	 the	
suggested	 method	 was	 calculated.	 The	 percentage	 relative	
error	calculated	using	the	following	equation:	
	
Er%	=	[(found	‐	added)	/	added]	×	100		 	 (1)	
	
The	 results	 of	 accuracy	 and	 precision	 show	 that	 the	
proposed	methods	have	good	repeatability	and	reproducibility,	
Table	7.	
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Table	3.	Determination	of	propafenone	HCl	and	diltiazem	HCl	using	NBD‐Cl.	
Statistics	 Spectrophotometric	method	 Spectrofluorimetric	method	
Propafenone	HCl	 Diltiazem	HCl Propafenone	HCl Diltiazem	HCl	
Taken	
μg/mL	
Recovery	*	
%	
Taken	
μg/mL	
Recovery	*	
%	
Taken	
μg/mL	
Recovery	*	
%	
Taken	
μg/mL	
Recovery	*	
%	
	 4	 99.37	 16 98.39 0.4 101.07 1.6	 100.91
	 16	 100.67	 32 100.98 0.8 100.92 2.4	 100.47
	 20	 99.06	 40	 99.00	 1.2	 99.88	 3.2	 100.25	
	 24	 100.95	 56	 100.31	 1.6	 99.36	 4.8	 99.16	
	 28	 99.76	 60	 100.52	 2.4	 99.33	 5.6	 98.47	
	 32	 99.67	 80 99.50 2.8 100.39 7.2	 101.64
	 44	 100.06	 88 99.38 3.6 100.14 8.0	 100.38
	 	 	 96 100.18 8.8	 99.36
Mean±S.D.	 99.93	±	0.680	 99.73	±	0.915	 100.16	±	0.690	 100.08±	1.023	
N	 7	 8	 7	 8	
V  0.462	 0.837	 0.476	 1.046	
S.D.	 0.680	 0.915 0.690 1.023	
R.S.D.	 0.680	 0.918 0.689 1.022	
S.E.	 0.257	 0.324 0.263 0.362	
*	Mean	of	three	different	experiments.	
	
Table	4.	Application	of	 standard	addition	 technique	 for	 the	determination	 of	propafenone	HCl	 and	diltiazem	HCl	 in	 their	 pharmaceutical	 formulations	using	
spectrophotometric	method. 
	 Propafenone	HCl	 Diltiazem	HCl
Rytmonorm	tablets	 Altiazem	tablets	 Delay‐tiazem	capsules	
Taken	 Added	 Recovery*	 Taken Added Recovery* Taken Added	 Recovery*
g/mL	 %	 g/mL %	 g/mL %	
	 8	 ‐‐	 99.81	 16 ‐‐ 100.18 16 ‐‐	 101.96
	 	 8	 100.44	 16 101.07 16	 101.07
	 	 24	 99.668	 32 100.08 32	 100.54
	 	 26	 98.07	 40 99.00 44	 99.41
	 	 28	 99.22	 44 101.36 52	 100.33
  	 32	 99.19	 	 48	 100.36	 	 56	 99.54	
	 	 36	 98.32	 52 99.51 64	 98.92
MeanS.D.	 99.150.874	 100.230.901	 99.970.805	
N	 6	 6 6
V	 0.765	 0.813 0.647
S.D.	 0.874	 0.901 0.805
S.E.	 0.357	 0.368 0.329
*	Mean	of	three	different	experiments.	
	
Table	 5.	 Application	 of	 standard	 addition	 technique	 for	 determination	 of	 propafenone	 HCl	 and	 diltiazem	 HCl	 in	 their	 pharmaceutical	 formulations	 using	
spectroflourimetric	method. 
	 Propafenone	HCl	 Diltiazem	HCl
Rytmonorm	tablets	 Altiazem	tablets Delay‐tiazem	capsules	
Taken	 Added	 Recovery*	 Taken	 Added	 Recovery*	 Taken	 Added	 Recovery*	
g/mL	 %	 g/mL %	 g/mL %	
	 0.8	 ‐‐	 99.43	 1.6 ‐‐ 100.91 1.6 ‐‐	 103.52
	 	 0.4	 98.11	 	 1.6	 100.91	 	 1.6	 98.29	
	 	 1.6	 100.10	 	 2.4	 98.72	 	 2.4	 100.47	
	 	 2	 98.46	 	 3.2	 98.94	 	 4	 99.07	
	 	 2.2	 97.59	 4 99.07 5.6	 100.12
  	 2.4	 99.34	 	 4.8	 100.03	 	 6.4	 99.97	
	 	 2.8	 99.54	 5.6 100.72 7.2	 100.58
MeanS.D.	 99.330.957	 99.730.951	 99.750.894	
N	 6	 6 6
V	 0.915	 0.905	 0.799	
S.D.	 0.957	 0.951 0.894
S.E.	 0.391	 0.388	 0.365	
*	Mean	of	three	different	experiments.	
	
	
The	 proposed	 methods	 were	 simple,	 accurate	 and	 the	
spectrofluorimetric	 method	 was	 more	 sensitive	 than	 the	
spectrophotometric	 one	 and	 both	 of	 them	 are	 suitable	 for	
analysis	of	the	selected	drugs	with	good	recoveries.	
	
3.3.	Kinetic	study	of	the	reaction	with	NBD‐Cl	
	
The	 rate	 of	 the	 reaction	 was	 found	 to	 be	 concentration	
dependent.	The	rate	of	the	reaction	was	followed	with	various	
concentrations	of	studied	drugs	in	the	range	of	4‐44	and	16‐96	
µg/mL	 for	 propafenone	 HCl	 and	 diltiazem	 HCl,	 respectively.	
The	graph	 shown	 in	Figure	3	and	4	 indicate	 that	 the	 reaction	
rate	of	propafenone	HCl	and	diltiazem	HCl	obeys	the	following	
equation:	
	
Rate=K`	[drug]n	 	 	 	 	 (2) 
	
where	K`	is	the	pseudo‐order	constant	of	the	reaction	and	n	is	
the	order	of	the	reaction.		
	
The	rate	of	the	reaction	may	be	estimated	by	the	variable‐
time	 method	 [68].	 In	 this	 method	 the	 reaction	 rate	 was	
followed	 by	measuring	 the	 change	 of	 absorbance	 at	 different	
time	 intervals	 Taking	 logarithms	 of	 rates	 and	 concentration	
(Table	8)	Equation	2	is	transformed	into:	
	
log	(rate)=log	∆A/∆t	=	log	K`	+	n	log	[drug]	 	 (3) 
	
where	A	is	the	absorbance	and	t	is	the	time	in	seconds.	
	
Regression	 of	 log	 (rate)	 versus	 log	 (drug)	 gave	 the	
regression	equations:	 
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Table	6.	Statistical	data	for	determination	of	propafenone	HCl	and	diltiazem	HCl	using	NBD‐Cl.	
ITEMS 
Propafenone	HCl	 Diltiazem	HCl	
Reference	
method	[3]	
	
Spectrophotometric	
method	
Spectrofluorimetric	
method	
Reference	
method	[1]	
	
Spectrophotometric	
method	
Spectrofluorimetr
ic	method	
Mean	
±S.D.	
100.29±	
0.630	
99.93±	0.680	 100.16±	0.690 99.38±	1.070 99.73	±	0.915 100.08	±	1.022
N	 3	 7	 7 4 8 8	
V	 0.395	 0.462	 0.476 1.140 0.837 1.046	
S.D.	 0.630	 0.680	 0.690 1.070 0.915 1.022	
t	 	 0.782	(2.306)*	 0.279	(2.306)*	 	 0.593	(2.228)*	 1.103	(2.228)*	
F	 	 1.170	(5.140)*	 1.205	(5.140)*	 	 1.362	(4.350)*	 1.090	(4.350)*	
*	Theoretical	values	of	t	and	F	at	P	=	0.05.	
	
Table	7.	The	intra‐day	and	inter‐day	accuracy	and	precision	data	for	propafenone	HCl	and	diltiazem	HCl	obtained	using	NBD‐Cl. 
	
Propafenone	HCl	 Diltiazem	HCl
Taken	
µg/mL	
Found	
µg/mL	
Recovery	
%	
RSD	
%	
Er	
%	
Taken	
µg/mL	
Found	
µg/mL	
Recovery	
%	
RSD	
%	
Er	
%	
Spectrophotometric		
method	
Intraday	
4	 3.98	 99.58 2.723 ‐0.42 16 15.74 98.39	 2.223 ‐1.61
16	 16.08	 100.51	 1.984	 0.51	 32	 32.22	 100.68	 1.956	 0.68	
20	 19.85	 99.23 1.044 ‐0.77 40 39.62 99.06	 1.801 ‐0.94
24	 24.18	 100.74 0.994 0.74 56 56.005 100.01	 1.190 0.01
Interday	
4	 3.97	 99.15	 2.735	 ‐0.85	 16	 15.84	 98.99	 2.530	 ‐1.01	
16	 16.16	 100.98 1.447 0.98 32 32.12 100.39	 2.060 0.39
20	 19.81	 99.06 1.840 ‐0.94 40 39.70 99.24	 1.773 ‐0.76
24	 24.15	 100.63 1.102 0.63 56 56.27 100.48	 1.587 0.48
Spectroflourimetric	
Method	
Intraday	
0.4	 0.404	 101.07 2.623 1.07 1.6 1.608 100.47	 3.050 0.47
0.8	 0.799	 99.93	 2.026	 ‐0.07	 2.4	 2.404	 100.18	 2.039	 0.18	
1.2	 1.199	 99.88 1.532 ‐0.12 3.2 3.215 100.47	 1.525 0.47
1.6	 1.592	 99.48	 1.283	 ‐0.52	 4.8	 4.767	 99.31	 1.796	 ‐0.69	
Interday	
0.4	 0.404	 101.07 2.623 1.07 1.6 1.615 100.91	 3.285 0.91
0.8	 0.797	 99.68	 2.382	 ‐0.32	 2.4	 2.418	 100.76	 3.366	 0.76	
1.2	 1.197	 99.72 2.539 ‐0.28 3.2 3.201 100.03	 2.099 0.03
1.6	 1.594	 199.61 2.033 ‐0.39 4.8 4.781 99.60	 2.271 ‐0.40
	
Table	8.	Logarithms	of	the	rates	for	different	concentrations	of	propafenone	HCl	and	diltiazem	HCl. 
Propafenone	HCl	 Diltiazem	HCl
Log	(rate),	log	∆A/∆t	 Log	[conc.]	(M)	 Log	(rate),	log	∆A/∆t Log	[conc.]	(M)	
‐4.429	 ‐4.927	 ‐4.311	 ‐4.450	
‐4.017	 ‐4.325	 ‐4.062 ‐4.149	
‐3.933	 ‐4.228	 ‐3.956	 ‐4.052	
‐3.861	 ‐4.149	 ‐3.799	 ‐3.906	
‐3.790	 ‐4.082	 ‐3.764	 ‐3.876	
‐3.749	 ‐4.024	 ‐3.671 ‐3.751	
‐3.574	 ‐3.885	 ‐3.619 ‐3.710	
‐	 ‐	 ‐3.588 ‐3.672	
	
	
	
	
Figure	 3.	 Absorbance	 versus	 time	 graphs	 for	 the	 reaction	 between	
propafenone	HCl	and	NBD‐Cl	at	different	concentrations	of	propafenone:	(1)	
1.183		10‐5	M.(2)	4.735		10‐5	M.	(3)	5.919		10‐5	M.	(4)	7.103		10‐5	M.	(5)	
8.287		10‐5	M.	(6)	9.470		10‐5	M.(7)	1.302		10‐4	M.	
	
	
log(rate)=	 0.2763	 +0.9955	 log	 C(r=0.9963),	 K`	 =	 1.889	 S‐1	 for	
propafenone	HCl	 	 	 	 	 (4)	
	
log	(rate)	=	‐0.1126	+	0.9462	log	C	(	r	=	0.9985),	K`	=	0.772	S‐1	
for	diltiazem	HCl	 	 	 	 	 (5)	
	
hence	 the	 reaction	 is	 first	 order	 (n	 ≈	 1)	with	 respect	 to	 drug	
concentration.	
3.3.1.	Evaluation	of	the	kinetic	methods 
	
The	quantitative	determination	of	the	studied	drugs	under	
the	optimized	experimental	 conditions	outlined	before,	would	
result	 in	 a	 pseudo‐first	 order	 reaction	 with	 respect	 to	 their	
concentration.	However,	the	rates	will	be	directly	proportional	
to	drug	concentration	 in	a	pseudo‐first	order	rate	equation	as	
follows:	
	
Rate=K`	[Mdrug]	 	 	 	 	 (6) 
	
where	K`	is	the	pseudo‐first	order	constant.	Equation	6	was	the	
basis	 for	 several	 experiments,	which	were	 run	 to	 obtain	drug	
concentration	 using	 the	 rate	 data.	 Rate	 constant,	 constant	
concentration	and	 fixed‐time	 [69,70]	were	 tried	 and	 the	most	
suitable	analytical	method	was	selected	taking	into	account	the	
applicability,	 the	 sensitivity,	 the	correlation	coefficient	 (r)	and	
the	intercept.	
	
3.3.2.	Rate‐constant	method	
	
Graphs	 of	 log	 (absorbance)	 versus	 time	 for	 the	 studied	
drugs	concentrations	 in	 the	range	1.184	x	10‐5	 to	1.302	x	10‐4	
and	 3.547	 x	 10‐5	 to	 2.129	 x	 10‐4	 M	 for	 propafenone	 HCl	 and	
diltiazem	HCl,	respectively,	were	plotted	and	all	appeared	to	be	
rectilinear.	Pseudo‐first	order	rate	constants	corresponding	to	
different	 drugs	 concentrations	 (C)	 were	 calculated	 from	 the	
slopes	 multiplied	 by	 ‐2.303	 and	 are	 presented	 in	 (Table	 9),	
(Figure	5	and	6).	
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Table	9.	Values	of	K`	calculated	from	slopes	of	log	A	vs.	t	graph	multiplied	by	‐2.303	for	different	concentrations	of	propafenone	HCl	and	diltiazem	HCl. 
Propafenone	HCl	 Diltiazem	HCl
K`	(S‐1)	 (M)	 K`	(S‐1) (M)	
‐3.18	x	10‐4	 1.18	x	10‐5	 ‐4.98	x	10‐4	 3.55	x	10‐5	
‐3.47	x	10‐4	 4.74	x	10‐5	 ‐5.49	x	10‐4	 7.09	x	10‐5	
‐3.44	x	10‐4	 5.92	x	10‐5	 ‐5.61	x	10‐4 8.87	x	10‐5	
‐3.43	x	10‐4	 7.10	x	10‐5	 ‐5.88	x	10‐4 1.24	x	10‐4	
‐3.52	x	10‐4	 8.29	x	10‐5	 ‐6.01	x	10‐4 1.33	x	10‐4	
‐3.61	x	10‐4	 9.47	x	10‐5	 ‐5.99	x	10‐4 1.77	x	10‐4	
‐4.01	x	10‐4	 1.30	x	10‐4	 ‐6.11	x	10‐4 1.95	x	10‐4	
‐	 ‐	 ‐6.01	x	10‐4 2.13	x	10‐4	
	
	
Table	10.	Values	of	reciprocal	of	time	taken	at	fixed	absorbance	for	different	rates	of	variable	concentration	of	propafenone	HCl	and	diltiazem	HCl.	
Propafenone	HCl  Diltiazem	HCl	
1/t	(S‐1)	 (M)	 1/t	(S‐1) (M)	
5.56	x	10‐4	 5.92	x	10‐5	 6.94	x	10‐4 7.09	x	10‐5	
6.67	x	10‐4	 7.10	x	10‐5	 9.26	x	10‐4 8.87	x	10‐5	
8.33	x	10‐4	 8.29	x	10‐5	 1.21	x	10‐3 1.24	x	10‐4	
9.25	x	10‐4	 9.47	x	10‐5	 1.27	x	10‐3 1.33	x	10‐4	
1.67	x	10‐3	 1.30	x	10‐4	 1.50	x	10‐3 1.77	x	10‐4	
‐	 ‐	 1.59	x	10‐3 1.95	x	10‐4	
‐	 ‐	 1.67	x	10‐3	 2.13	x	10‐4	
	
	
	
	
	
Figure	4.	Absorbance	versus	time	graphs	for	the	reaction	between	diltiazem	
HCl	 and	 NBD‐Cl	 at	 different	 concentrations	 of	 diltiazem:	 (1)	 3.547	 	 10‐5	
M.(2)	7.095		10‐5	M.	(3)	8.869		10‐5	M.	(4)	1.242		10‐4	M.	(5)	1.330		10‐4	
M.	(6)	1.774		10‐4	M.(7)	1.951		10‐4	M.	(8)	2.129		10‐4	M.	
	
	
	
	
Figure	5.	Values	of	k`(s‐1)	calculated	from	slopes	of	different	log	absorbance	
vs	 t	 graph	multiplied	by	 ‐2.303	 for	different	 concentrations	of	propafenone	
HCl:	(1)	1.183		10‐5	M.	(2)	4.735		10‐5	M.	(3)	5.919		10‐5	M.	(4)	7.103		10‐5	
M.(5)	8.287		10‐5	M.(6)	9.470		10‐5	M.(7)	1.302		10‐4	M.	
	
Regression	of	(C)	versus	K`	gave	the	equation:	
	
K`=	‐	0.0003	‐	0.6317	C	(r=0.9443)	(for	propafenone	HCl)	 (7)	
	
K`=	‐	0.0005	‐	0.5438	C	(r=0.8974)	(for	diltiazem	HCl)	 (8)	
	
The	 value	 (r)	 indicates	 poor	 linearity,	 which	 is	 probably	
due	to	inconsistency	of	K`.	
	
3.3.3.	Fixed‐concentration	method	
	
Reaction	 rates	 were	 determined	 for	 different	
concentrations	 in	 the	 range	 1.184	 x	 10‐5	 to	 1.302	 x	 10‐4	 and	
3.547	 x	 10‐5	 to	 2.129	 x	 10‐4	 M	 for	 propafenone	 HCl	 and	
diltiazem	 HCl,	 respectively.	 A	 pre‐selected	 value	 of	 the	
absorbance	was	 fixed	and	 the	 time	was	measured	 in	 seconds.	
The	reciprocal	of	time	(i.e.	1/t)	versus	the	initial	concentration	
of	 the	 studied	 drugs	 (Table	10)	was	plotted	 (Figure	7	 and	8).	
The	 following	 equations	 for	 calibration	 graphs	 were	 worked	
out	by	linear	regression:		
	
1/	t	=	0.0003+	15.759	C	(r=0.9843)	for	propafenone	HCl	 (9)	
	
1/	t	=	0.0003+	6.5346	C	(r=0.9847)	for	diltiazem	HCl	 (10) 
	
The	range	of	the	concentration	of	the	studied	drugs	giving	
the	most	acceptable	calibration	graph	with	the	above	equations	
was	very	limited,	which	could	be	disadvantage.	
	
	
	
Figure	6.	Values	of	k`(s‐1)	calculated	from	slopes	of	different	log	absorbance	
vs	t	graph	multiplied	by	‐2.303	for	different	concentrations	of	diltiazem	HCl:	
(1)	3.547		10‐5	M.(2)	7.095		10‐5	M.	(3)	8.869		10‐5	M.	(4)	1.242		10‐4	M.	
(5)	1.330		10‐4	M.	(6)	1.774		10‐4	M.(7)	1.951		10‐4	M.	(8)	2.129		10‐4	M.	
	
3.3.4.	Fixed	time	method	
	
Reaction	rates	were	determined	for	different	concentration	
of	 the	 studied	 drugs.	 At	 a	 pre‐selected	 fixed	 time,	which	was	
accurately	 determined,	 the	 absorbance	 was	 measured.	
Calibration	 graphs	 of	 the	 absorbance	 versus	 initial	
concentration	of	the	studied	drugs	were	obtained	at	fixed	times	
of	10,	20,	30	and	40	min	with	the	calibration	equation	shown	in	
(Table	11).		
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Table	11.	Calibration	equations	at	different	fixed	time	over	the	range	of	1.18	
x	10‐5	 ‐	1.30	x	10‐4	and	3.55	x	10‐5	 ‐	2.13	x	10‐4	M	 for	propafenone	HCl	and	
diltiazem,	respectively. 
Time	(min)	 Calibration	equation	 Correlation	coefficient	(r)
Propafenone	HCl 
10  A	=	0.0675	+	0.0096	C 0.9949 
20	 A	=	0.0615	+	0.0145	C	 0.9989 
30	 A	=	0.0827	+	0.0197	C	 0.9999	
40	 A	=	0.0791	+	0.0198	C  0.9994 
Diltiazem	HCl 
10	 A	=	0.0311	+	0.0197	C	 0.9986	
20	 A	=	0.0118	+	0.0058	C	 0.9989 
30	 A	=	0.0428	+	0.0070	C	 0.9999 
40	 A	=	0.0426	+	0.0067	C  0.9990	
	
	
	
	
Figure	7.	Values	of	reciprocal	of	time	taken	at	fixed	absorbance	for	different	
rates	of	variable	concentrations	of	propafenone	HCl.	
	
	
	
	
Figure	8.	Values	of	reciprocal	of	time	taken	at	fixed	absorbance	for	different	
rates	of	variable.	
	
	
It	is	clear	that,	both	the	slopes	and	intercepts	increase	with	
time.	The	most	acceptable	values	of	 the	correlation	coefficient	
and	more	 reaction	 products	 (indicated	 by	 higher	 absorbance	
readings)	 as	 shown	 in	 (Figure	 3	 and	 4)	 were	 obtained	 for	 a	
fixed	time	of	30	min,	which	was,	 therefore	chosen	as	the	most	
suitable	time	interval	for	measurements. 
After	 optimizing	 the	 reaction	 conditions,	 the	 fixed	 time	
method	was	applied	 to	 the	determination	of	propafenone	HCl	
and	 diltiazem	 HCl	 in	 pure	 form	 and	 in	 pharmaceutical	
formulation	 over	 the	 concentration	 range	 of	 (4‐44	 and	 16‐96	
μg/mL)	for	both	drugs	respectively.		
Analysis	 of	 the	 date	 gives	 the	 following	 regression	
equation: 
	
A	=0.0827	+	0.0197	C(r=	0.9999)	for	propafenone	HCl	 (11)	
	
A	=	0.0428	+	0.0070	C(r	=	0.9999)	for	diltiazem	HCl	 (12)	
	
The	fixed	time	method	was	applied	to	the	determination	of	
the	 studied	 drugs	 in	 the	 pure	 form	 and	 in	 the	 supplied	 drug	
formulations.	 The	 concentrations	 of	 the	 studied	 drugs	 were	
calculated	using	the	corresponding	calibration	equation	at	fixed	
time	of	30	min.	The	developed	analytical	method	was	validated.	
Under	 the	 described	 experimental	 conditions,	 calibration	
graphs	 were	 constructed	 for	 all	 of	 the	 studied	 drugs;	 linear	
relationship	was	found	between	the	absorbance	at	λmax	and	the	
concentration	 of	 the	 drug	 (Table	 1).	 The	 recoveries,	 standard	
deviations,	 relative	 standard	 deviations,	 standard	 errors,	
variances	 for	 the	 two	 studied	 drugs	 applying	 the	 previously	
stated	methods	were	listed	in	(Table	3).	The	proposed	methods	
were	 applied	 for	 determination	 of	 the	 selected	 drugs	 in	 their	
pharmaceutical	 formulations	 using	 the	 standard	 addition	
method.	The	results	of	analysis	of	the	commercial	dosage	forms	
and	 the	 recovery	 study	 are	 shown	 in	 (Table	 4	 and	 5).	 The	
average	 percent	 recoveries	 obtained,	 indicated	 good	 accuracy	
of	the	methods.	 
The	result	obtained	for	the	analysis	of	the	studied	drugs	in	
drug	 formulations	 employed	 was	 compared	 with	 those	
obtained	with	 the	official	 and	 reference	methods	 [1,3],	 (Table	
6).	The	Student	t‐test	and	F‐test	values	of	95%	confidence	level	
did	 not	 exceed	 the	 theoretical	 values	 indicating	no	 significant	
difference	between	 the	 accuracy	 and	 the	 precision	 of	 the	 two	
methods.	
	
4.	Conclusion	
	
The	 proposed	 method	 holds	 several	 advantages	 when	
compared	 to	 other	 previously	 reported	 methods,	 such	 as	
sensitivity	and	selectivity.	In	contrast	to	HPLC,	there	is	no	need	
for	 special	 hardware,	 or	 expensive	 solvent.	 In	 conclusion,	 the	
given	data	reveal	that	the	proposed	methods	are	accurate	and	
sensitive,	 with	 good	 precision	 and	 accuracy.	 With	 these	
methods,	 one	 can	 do	 accurate	 analysis	 at	 low	 cost	 without	
losing	 accuracy.	 The	 proposed	 methods	 can	 be	 used	 for	 the	
routine	 analysis	 of	 the	 cited	 drugs	 in	 the	 pure	 form	 and	 in	
pharmaceutical	formulations,	in	quality	control	laboratories,	or	
on	smaller	scale	in	small	laboratories.	
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